Our Approach

New Science Ventures, LLC (NSV) is a New York and London-based venture capital firm which invests in companies using novel scientific approaches in the Life Sciences and Information Technology sectors

Learn More

News

April 8, 2021
Achronix now shipping industry’s highest performance Speedster7t FPGA devices

Santa Clara, Calif., April 8, 2021 – Achronix Semiconductor Corporation, a leader in high-performance FPGAs and embedded FPGA (eFPGA) IP, today announced that it has begun shipping its 7nm Speedster®7t AC7t1500 FPGAs to customers ahead of schedule. The Speedster7t family is purpose-built for high bandwidth workloads in a broad range

Read More
March 25, 2021
ABL Space raises $170m growth equity round led by T. Rowe Price funds

EL SEGUNDO, Calif., March 25, 2021 /PRNewswire/ -- ABL Space Systems has closed a Series B investment round of $170 million at a valuation of $1.3 billion. The round was led by funds and accounts advised by T. Rowe Price Associates, Inc. Participation in the round included existing ABL investors

Read More
March 16, 2021
Ventyx Biosciences doses first subject in a Phase 1 Trial of VTX-958, a selective allosteric TYK2 Inhibitor for Autoimmune Diseases

Study to evaluate pharmacokinetics, safety and tolerability of VTX-958 as well as effects on biomarkers of TYK2-driven inflammatory signaling ENCINITAS, March 16, 2021 /PRNewswire/ —  Ventyx Biosciences, Inc. a clinical-stage biotechnology company developing oral, small molecule therapeutics for autoimmune disease, today announced the dosing of the first subject in a

Read More
March 9, 2021
New Science Ventures Portfolio Company Ventyx Biosciences Raises $114 Million

New York (NY, US), London (UK), March 9th, 2021 – New Science Ventures LLC (“NSV”), a leading venture capital firm focused on building companies that leverage breakthrough science to create extraordinary value, announces that its portfolio company Ventyx Biosciences raised $114 million from blue-chip investors to advance a diverse pipeline

Read More
March 8, 2021
iCAD – New research supporting ProFound AI presented at European congress of radiology online meeting

iCAD showcased expanded ProFound AI platform, including ProFound AI Risk, the world’s first clinical decision support tool that provides a highly accurate short-term risk estimation specific to each woman. NASHUA, N.H. – March 8, 2021 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and

Read More
March 8, 2021
Isorg obtains FBI certification for security market’s first organic photodiode-based module for fingerprint scanners

US approval of FAP 10 module, first in a new category of optical sensors, is approbation that global biometrics market is ready for organic electronics in security applications. Limoges, France, March 8, 2021 – Isorg, a pioneer in organic photodetectors (OPDs) and large-area image sensors, today announces its Fingerprint Acquisition

Read More
March 8, 2021
iCAD announces closing of $25.0 million public offering of common stock and full exercise of underwriters’ option to purchase additional shares

NASHUA, N.H., March 08, 2021 -- iCAD, Inc. (the “Company”, NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the closing on March 5, 2021 of its previously announced underwritten public offering of 1,393,738 shares of common stock at a public offering price

Read More
February 11, 2021
ProterixBio announces commercial availability of a quantitative COVID-19 serology test validated for dried blood spots from a finger stick

Billerica, MA, February 11, 2020: ProterixBio, Inc. announced today commercial availability of a quantitative COVID-19 serology assay that has been validated for dried blood spots (DBS) from a finger stick. This is an update to the previously released SARS-CoV-2 (RBD) IgG Antibody test and is being offered as a testing

Read More
January 26, 2021
DataCore Software acquires Caringo, Inc.

DataCore Software, the authority on software-defined storage, today announced that it has acquired Caringo, Inc. The combined entity will enable DataCore to offer complete, best-of-breed software-defined storage solutions for block, file, and object—from a single vendor. The acquisition will also add talent and expertise to the DataCore team, as well

Read More
January 12, 2021
New Science Ventures announces merger of its portfolio company Achronix with ACE Convergence

New York (NY, US), London (UK), January 12, 2021 – New Science Ventures LLC (“NSV”), a leading venture capital firm focused on building companies that leverage breakthrough science to create extraordinary value, today announces the merger of its portfolio company, Achronix Semiconductor Corporation (“Achronix”), with ACE Convergence Acquisition Corp. NSV

Read More
January 8, 2021
NorthSea Therapeutics reports Positive Phase 2b interim results for icosabutate in NASH patients

Icosabutate demonstrates potent anti-inflammatory, anti-fibrotic and antioxidant properties, and shows improvement in cardio-metabolic risk profile Interim readout based on the first 90 patients treated for 16 weeks Once-daily oral icosabutate showed dose-dependent, significant, and clinically meaningful improvements in all liver function chemistry, and inflammatory and fibrotic biomarkers with a remarkable

Read More
January 6, 2021
TigerConnect acquires Critical Alert

SANTA MONICA, California — January 6, 2021 — TigerConnect®, healthcare’s most advanced, reliable, and widely adopted care team collaboration solution, today announced the acquisition of Critical Alert®, a leading provider of enterprise-grade middleware for hospitals and health systems. Critical Alert’s product suite consists of a middleware suite of products as

Read More
December 9, 2020
Resolve Therapeutics announces clinically meaningful improvement in patients with Systemic lupus erythematosus in Phase 2a clinical trial

Resolve Therapeutics, pioneering first-in-class, targeted, safe therapies for underserved autoimmune diseases, today announced results from its Phase 2a study of RSLV-132 in patients with Systemic lupus erythematosus (SLE). Sixty-six patients diagnosed with SLE and a CLASI score of ≥ 10 at screening were enrolled into the study at 19 clinical

Read More
December 3, 2020
Resolve Therapeutics publishes positive Sjogren’s syndrome clinical trial results

Resolve Therapeutics, pioneering first-in-class, targeted, safe therapies for underserved autoimmune diseases, today announced publication of results from its Phase 2 study of RSLV-132 for the treatment of primary Sjogren’s syndrome (pSS).  The work was published in the leading rheumatology journal, Arthritis and Rheumatology (doi.org/10.1002/art.41489).  The Phase 2 study demonstrated a

Read More
November 20, 2020
NorthSea Therapeutics doses first patient in Phase 1 trial of SEFA-1024 in dyslipidemia and further expands its clinical pipeline

NST becomes a multi-asset clinical development company, beyond NASH Pre-clinical studies have demonstrated broad and marked beneficial effects of SEFA-1024 on non-HDL cholesterol, triglycerides, and HDL cholesterol and glycemic control A third clinical development program, SEFA 6179, for treating Intestinal Failure- Associated Liver Disease (IFALD) will start Phase 1 studies

Read More
September 28, 2020
ProterixBio Announces Commercial Availability of a Semi-Quantitative COVID-19 Antibody Test

Billerica, MA, September 29, 2020: ProterixBio, Inc. announced today commercial availability of the SARS-CoV-2 (RBD) IgG Antibody test, a semi-quantitative COVID-19 serology assay. It is being offered as a testing service through ProterixBio’s high-complexity clinical testing laboratory. Validation results demonstrated a Positive Percent Agreement (PPA) of 100% for samples acquired

Read More
September 2, 2020
Amarisoft and Dali Wireless Collaborate to Deliver Open RAN Based 4G and 5G Solutions

Interoperability and co-marketing initiatives will bring new options for enterprises, and mobile network operators deploying in-building cellular solutions Menlo Park, California and Paris, France – February 11, 2020 – Dali Wireless, a global leader in wireless fronthaul innovation for virtual RAN, and Amarisoft, a pioneer in software centric 4G LTE

Read More
July 1, 2020
ProterixBio licenses COVID-19 serology test from Massachusetts General Hospital

Billerica, MA, July 1, 2020: ProterixBio, Inc. today announced completing a licensing agreement with the Massachusetts General Hospital for a COVID-19 serology assay. The assay was developed and validated by researchers at the Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University which is a joint

Read More
June 25, 2020
Oppilan Pharma Announces Positive Phase 1 Data for its Ulcerative Colitis Drug OPL-002 at Digestive Disease Week 2020 Virtual Scientific Program

Potential best-in-class profile for an oral sphingosine-1-phosphate receptor modulator – Dose-dependent reduction in circulating lymphocytes –– Rapid lymphocyte recovery after cessation of dosing –– Phase 2 study in ulcerative colitis patients in 4Q 2020 – ENCINITAS, California and Cambridge, United Kingdom, June 23, 2020 – Oppilan Pharma, Ltd., a clinical-stage

Read More
Previous Next

Our Companies

We focus on sectors that have strong decades-long tailwinds, where we have direct experience and where we can leverage our strong external networks to create value

Learn More

Our Team

The team brings a wealth of investment experience and board expertise in the life sciences and information technology sectors across US and Europe

Learn More

Contact Us

New York

299 Park Avenue, 41st Floor, New York, NY 10171
T: 212 688 5100 F: 212 308 9196

London

16 Old Queen Street, London SW1H 9HP
T: 020 3981 9092 F: 020 3981 9100